Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. The Lancet. Published online, 12 February 2015 – Please find attached analysis of the recent published paper in The Lancet which discusses HRT and ovarian cancer risk.This includes:
- A statement from IMS President, Dr Rodney Baber outlining the IMS position.
- A statement issued jointly from the British Menopause Society and the Royal College of Gynaecologists in the UK which may be helpful in explaining this research and providing reassurance to worried patients.
- A review of the Lancet paper, and how the UK press reacted to it, from the NHS’s “Behind the headlines” group which analysis current research and how the press report it (http://www.nhs.uk/news/2015/02February/Pages/HRT-increases-ovarian-cancer-risk-by-small-amount.aspx).
A full analysis of the paper will feature in the next issue of Menopause Live.Any queries, please contact Lee Tomkins, Executive Director for further information email@example.com.